Avapag 20 mg Tablets (Avatrombopag)

PDGFRA and KIT testing actually serves two quite different purposes depending on which disease is being investigated — for GIST, it’s about characterizing an already-identified tumor; for systemic mastocytosis, the KIT mutation is often central to making the diagnosis itself.

What’s being tested — and why GIST and mastocytosis are different here

KIT and PDGFRA are related genes that both encode receptor tyrosine kinases — proteins on the cell surface involved in growth signaling. Mutations in either gene can drive uncontrolled cell growth, but the specific mutations relevant to GIST and mastocytosis are largely distinct.

For GIST: KIT mutations account for roughly 70-80% of cases, most commonly in exon 11, while PDGFRA mutations account for about 10%, with exon 18 (including D842V) being the clinically important one for Avatrombopag eligibility. A GIST tumor could have mutations in either gene, in different exons, each with different drug sensitivities — which is why broad mutation testing (not just “KIT positive/negative”) matters.

For systemic mastocytosis: the picture is much more singular — KIT D816V is present in the vast majority of systemic mastocytosis cases and is considered a defining molecular feature of the disease, used as part of the diagnostic criteria itself, not just a treatment-selection marker.

Sample source

GIST: testing is done on tumor tissue — from a biopsy or, more often, the surgical resection specimen if the tumor was removed. Since GIST is a solid tumor, there’s no blood-based equivalent for initial diagnosis.

Mastocytosis: testing typically starts with peripheral blood for an initial KIT D816V screen, since highly sensitive PCR methods can detect this mutation even at very low levels in blood. However, a bone marrow biopsy is generally required for a definitive diagnosis and to assess disease subtype (indolent vs advanced), since mastocytosis is a bone marrow-based disease and blood testing alone doesn’t capture the full picture.

How the lab analyzes it

For GIST:

• Immunohistochemistry (IHC) for KIT (CD117) and DOG1 proteins is often the first step — this confirms the tumor is a GIST at all (most GISTs stain positive for these markers), but doesn’t identify the specific mutation
• PCR-based sequencing or NGS panels are then used to identify the specific KIT exon (9, 11, 13, or 17) or PDGFRA exon (12, 14, or 18) mutation — this is the step that determines drug sensitivity

For mastocytosis:

• Highly sensitive allele-specific PCR (sometimes called ddPCR or similar ultra-sensitive techniques) is commonly used for KIT D816V, because this method can detect the mutation even when only a small fraction of cells carry it — important since mast cells may be a minority population in the marrow
• NGS panels are also used, particularly to rule out additional mutations that might indicate an associated hematologic neoplasm (a more advanced subtype)
• Serum tryptase levels are measured as a supporting biomarker — not a mutation test, but an important part of the overall diagnostic picture for mastocytosis

Timeline

GIST: IHC results often return within days, while mutation sequencing (PCR or NGS) typically takes 1-3 weeks.

Mastocytosis: peripheral blood KIT D816V PCR can sometimes return in under a week given how targeted the test is, while a full bone marrow workup with NGS may take 2-3 weeks.

What the result means for treatment

A practical nuance

For GIST specifically, a common point of confusion is that a positive CD117/KIT IHC stain (confirming the tumor is a GIST) is sometimes mistaken for confirmation of a KIT mutation — these are different things. IHC tells you what the tumor is; mutation sequencing tells you which specific gene and exon is altered, which is what actually determines drug selection. If your pathology report only mentions IHC results without a specific mutation (like “KIT exon 11” or “PDGFRA D842V”), that’s worth clarifying with your oncologist before assuming a particular drug applies.